Top News

Pfizer to Acquire Biohaven Pharmaceuticals for $11.7 Billion

May 16, 2022

Pfizer will acquire Biohaven Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in migraine treatments, for $11.7 billion.

FDA Limits Use of Janssen COVID-19 Vaccine

May 06, 2022

FDA is limiting the use of Janssen’s COVID-19 vaccine to certain individuals.

Purolite Awarded Queen’s Award for Enterprise

May 05, 2022

Purolite has received the Queen’s Award for Enterprise in the International Trade category.

Moderna Submits EUA of COVID-19 Vaccine for Use in Young Children

May 02, 2022

Moderna has filed for emergency use authorization of its COVID-19 vaccine for use in young children six months to under six years of age.

FDA Approves Veklury for Treatment of COVID-19 in Pediatric Patients

April 25, 2022

FDA has approved Veklury to treat COVID-19 in pediatric patients under 12 years of age.

Catalent to Invest $350 Million in Manufacturing Facility in Bloomington, Indiana

April 22, 2022

Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.

ReiThera and Exothera Collaborate on Manufacturing Vaccines for Low and Middle-income Countries

April 14, 2022

ReiThera and Exothera are collaborating to develop a large-scale, low-cost-per-dose manufacturing process to deliver novel vaccines to low and middle-income countries.

Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

April 13, 2022

Swissmedic grants conditional marketing authorization for Novavax COVID-19 vaccine for individuals aged 18 years or older in Switzerland.

UK Government Awards £15.9 million grant to Chemical Producer Croda

April 05, 2022

UK government has awarded chemical producer Croda a £15.9 million grant to increase the UK’s capacity to manufacture key vaccine ingredients.

Novavax and Serum Institute of India Announce Emergency Use Authorization of Novavax’ COVID-19 Vaccine in Adolescents Ages 12 to 18 in India

March 30, 2022

Novavax’ COVID-19 vaccine has been granted emergency use authorization for use in the adolescent population ages 12–18 in India.